Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This study (ARD-3150-1201, ORBIT-3) will evaluate the safety and efficacy of inhaled
Pulmaquin (ciprofloxacin dispersion for inhalation) compared to inhaled placebo in subjects
who have a confirmed diagnosis of non-cystic fibrosis (non-CF) bronchiectasis with a history
of pulmonary exacerbations and chronic P. aeruginosa infections.
Phase:
Phase 3
Details
Lead Sponsor:
Aradigm Corporation
Collaborators:
Grifols Therapeutics Inc. Grifols Therapeutics LLC